Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase

Clinical Chemistry

Volumn 49, Issue 10, 2003, Pages 1661-1664

  Ahluwalia, Ranjeet ^a   Freimuth, Robert ^a   McLeod, Howard L ^a   Marsh, Sharon ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; PYRIMIDINE DERIVATIVE;

ABSORPTION; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; GENE FREQUENCY; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME; HUMAN; MICROCEPHALY; MONONUCLEAR CELL; NEUROTOXICITY; NONHUMAN; POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY;

AFRICAN CONTINENTAL ANCESTRY GROUP; CHROMOSOMES, HUMAN, PAIR 20; DIHYDROURACIL DEHYDROGENASE (NADP); EUROPEAN CONTINENTAL ANCESTRY GROUP; FLUOROURACIL; GENE FREQUENCY; GENOTYPE; HUMANS; METABOLIC DETOXICATION, DRUG; OXIDOREDUCTASES; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

EID: 0141615759     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.10.1661     Document Type: Article

References (21)

1. Weber BL. Cancer genomics [Review]. Cancer Cell 2002;1:37-47.
2. Marth GT, Korf I, Yandell MD, Yeh RT, Gu Z, Zakeri H, et al. A general approach to single nucleotide polymorphism discovery. Nat Genet 1999;23:452-6.
3. Brookes AJ. The essence of SNPs. Gene 1999;234:177-86.
4. The International SNP Map Working Group. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409:928-33.
5. Marth G, Yeh R, Minton M, Donaldson R, Li Q, Duan S, et al. Single nucleotide polymorphisms in the public domain: how useful are they? Nat Genet 2001;27:371-2.
6. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
7. Lennard L, Van Loon JA, Wienshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54.
8. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716-8.
9. Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 1998;46:151-6.
10. Iyer L, Das S, Janisch L, Wen M, Ramirez T, Karrison G, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics 2002;2:43-7.
11. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60:6921-6.
12. Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez-Salguero P, et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 1998;51:391-400.
13. Collie-Duguid ESR, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000;10:217-23.
14. McLeod HL, Collie-Duguid ESR, Vreken P, Johnson MR, Wei X, Sapone A, et al. Nomenclature for human DPYD alleles. Pharmacogenetics 1998;8:455-9.
15. Ronaghi M. Pyrosequencing sheds light on DNA sequencing [Review]. Genome Res 2001;11:3-11.
16. Pyrosequencing Inc. homepage. http://www.pyrosequencing.com. (Accessed March 2003).
17. Shan PC, Curtis D. Monte Carlo tests for associations between diseases and alleles at highly polymorphic loci. Ann Hum Genet 1995;59:97-105.
18. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS, et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2CI9, CYP2EI) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 2002;53:596-603.
19. Judson R, Stephens JC. Notes from the SNP vs. haplotype front. Pharmacogenomics 2001;2:7-10.
20. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nanadabalan K, et al. Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responses. Proc Natl Acad Sci U S A 2000;97:10483-8.
21. Schaid DJ, McDonnell SK, Wang L, Cunningham JM, Thibodeau SN. Caution on pedigree haplotype inference with software that assumes linkage equilibrium. Am J Hum Genet 2002;71:992-5.